Provided by Tiger Fintech (Singapore) Pte. Ltd.

COSCIENS Biopharma Inc

3.61
-0.1099-2.95%
Volume:3.25K
Turnover:11.87K
Market Cap:11.36M
PE:-0.60
High:3.79
Open:3.72
Low:3.56
Close:3.72
Loading ...

Cosciens Biopharma announces receipt of Goodwood intended director nominations

TIPRANKS
·
26 May

Press Release: Goodwood to Nominate New Directors for COSCIENS Biopharma Inc.

Dow Jones
·
24 May

Cosciens Biopharma Q1 EPS $(1.16) Up From $(4.74) YoY, Sales $1.50M Up From $4.00K YoY

Benzinga
·
14 May

Cosciens Biopharma Names Anna Biehn as Chief Executive

Dow Jones
·
14 Apr

Cosciens Biopharma appoints Biehn as CEO

TIPRANKS
·
14 Apr

COSCIENS Biopharma Inc. Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer

GlobeNewswire
·
14 Apr

COSCIENS Biopharma Full Year 2024 Earnings: US$5.93 loss per share (vs US$13.64 loss in FY 2023)

Simply Wall St.
·
12 Apr

COSCIENS Biopharma Q4 EPS $(2.15) Down From $(0.85) YoY, Sales $3.30M Up From $1.20M YoY

Benzinga
·
10 Apr

AEterna Zentaris Q4 EPS $(2.15) Down From $(0.85) YoY, Sales $3.30M Up From $1.20M YoY

Benzinga
·
10 Apr

COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

GlobeNewswire
·
10 Apr

COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order

GlobeNewswire
·
02 Apr

Cosciens Biopharma to Start Phase 2a of Inflammation Drug Candidate

MT Newswires Live
·
13 Mar

COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product

GlobeNewswire
·
13 Mar

Press Release: Perrigo Provides Detailed Plan to Consumerize, Simplify and Scale its Unique Global Self-Care Platform at its Virtual Investor Day

Dow Jones
·
28 Feb

Cosciens Biopharma provides update, reiterates pipeline prioritization

TIPRANKS
·
23 Dec 2024

COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization

GlobeNewswire
·
23 Dec 2024